CD33 and glioblastoma: Patients with freshly detected GBM had an augmented quantity of circulating CD33+ HLA-DR2 MDSCs in their blood which comprises of neutrophilic (CD15+) and immature (CD152 and CD142), as well as monocytic (CD14+) subsets [22].